<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body> <br /> Synthesis, Analysis Toxicity Compounds <br /> Formed Synthesis lodixanol <br />  <br />  <br />                                 Priebe, H., Dugstad, H., Heglund,  F., Sande, R. Tenseth, C. P., 1995. <br />                                 Synthesis, Analysis Toxicity Compounds Formed Syn- <br />                                 thesis Iodixanol. - Acta Chern. Scand. 49: 737-743 &#194;&#169; Acta Chemica Scan- <br />                                 dinavica 1995. <br />                                 origin 4-acetyl-2-[N-acetyl-3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6- <br />                                 triiodoanilinomethyl ]-5,7-diiodo-3,4-dihydro-2H-benzo[ 1,4]oxazine-6,8-dicarbox- <br />                                 ylic acid bis(2,3-dihydroxypropylamide):;:: N-acetyl cyclized iodixanol, 2-[N- <br />                                 acetyl-3,5-bis-(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodoanilinomethyl]-5,7- <br />                                 diiodo-3,4-dihydro-2H-benzo[ 1,4]oxazine-6,8-dicarboxylic acid bis(2,3-dihydroxy- <br />                                 propylamide):::: cyclized iodixanol 5,5&apos; -(N-acetyl-2-hydroxypropane-l,3- <br />                                 diyldiamino )bis[N,N&apos; -bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide] = <br />                                 deacetyl iodixanol manufacturing process X-ray contrast agent <br />                                 3,3&apos; ,5,5&apos; -tetrakis(2,3-dihydroxypropylcarbamoyl)-2,2&apos; ,4,4&apos; ,6,6&apos; -hexaiodo-N,N&apos; - <br />                                 (2-hydroxypropane-l,3-diyl)diacetanilide = iodixanol discussed syn- <br />                                 thesis purification described. physical toxicological properties, <br />                                 analytical spectroscopic data summarized. <br />  <br />  <br />  <br /> X-Ray contrast agents generally contain heavy atoms                         nomethyl ]-5,7-diiodo-3,4-dihydro-2H-benzo[ 1,4]oxazine- iodine X-ray absorbent hydrophilic                        6,8-dicarboxylic acid bis(2,3-dihydroxypropylamide). <br /> parts like carboxylic acid, carboxamide hydroxy                             2 = Cyclized iodixanol = 2-[N-acetyl-3,5-bis(2,3-dihy- <br /> groups achieve good water solubility. type hy-                    droxypropylcarbamoyl) - 2,4,6 - triiodoanilinomethyl] - 5,7- <br /> drophilic group classifies tri-iodinated aromatic com-                    diiodo-3,4-dihydro-2H-benzo[ 1,4]oxazine-6,8-dicarboxy- <br /> pound ionic (1st generation) non-ionic (2nd gen-                   lie acid bis(2,3-dihydroxypropylamide). <br /> eration) contrast agent. generation X-ray contrast                       3 = Deacetyl iodixanol = 5,5&apos; -(N-acetyl-2-hydroxyprop- <br /> agents iodixanol 1 dimers non-ionic tri-                     ane-1,3-diyldiamino )bis[N,N&apos; -bis(2,3-dihydroxypropyl)- <br /> iodinated aromatic compounds pharmaceutical                        2,4,6-triiodoisophthalamide]. <br /> mulation 2 isotonic 3 isoosmotic 4 blood.                    4 = Compound 5400 = 5-amino-N,N&apos; -bis(2,3-dihydro- <br />    order avoid presence toxic components                    xypropyl)-2,4,6-triiodo-isophthalamide. iodixanol drug substance impurities degradation                     5 = TFA-allyl-5400 = 5-(N-allyl-2,2,2-trifluoroacetami- <br /> products certain concentration level charac-                    )-N,N&apos; -bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthal- <br /> terized origin, synthesis analytical, spectro-                 amide. <br /> scopic toxicological properties. N- Acetyl cyclized io-                    6 = Compound 5410 = 5-acetamido-N,N&apos; -bis-(2,3-di- <br /> dixanol 1, cyclized iodixanol 2 deacetyl iodixanol 3                    hydroxypropyl)-2,4,6-triiodo-isophthalamide. representatives possible impurities io-                    7 = TFA-5400-bromohydrin = 5-[N-(3-bromo-2-hydro- <br /> dixanol process. formed synthe-                      xypropyl)-2,2,2-trifluoroacetamido ]-N,N&apos; -bis-(2,3- <br /> sis 5 degradation iodixanol. molecular struc-                dihydroxypropyl)-2,4,6-triiodoisophthalamide. <br /> tures summarized Fig. 1.                                                8 = Iodixanol = 3,3&apos; ,5,5&apos; -tetrakis(2,3-dihydroxy- <br />    text molecule numbers trivial names                 propylcarbamoyl)-2,2&apos; ,4,4&apos; ,6,6&apos; -hexaiodo-N,N&apos; -(2- <br /> abbreviations used instead corresponding IV-                     hydroxypropane-1,3-diyl)diacetanilide. <br /> PAC names. 6 intercorrelation given                             9 = Peracetyl cyclized iodixanol = <span id='am-12' about='obo:IMR_0200208' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-13' property="oboInOwl:hasDbXref" content="KEGG:C00033" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:id" content="IMR:0200208" datatype="xsd:string"></span><span id='am-15' property="rdfs:label" content="Acetic acid" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>acetic acid</span> 2-acetoxy- <br />    1 = N-acetyl cyclized iodixanol = 4-acetyl-2-[N-acetyl-                  3- [3-{ acetyl-[ 4-acetyl-6,8-bis-(2,3-diacetoxypropyl- <br /> 3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodoanili-                   carbamoyl)-5,7-diiodo-3,4-dihydro-2H-benzo[ 1,4]oxazin- <br />                                                                             2-ylmethyl]amino}-5-(2,3-diacetoxypropylcarbamoyl)- <br />                                                                             2,4,6-triiodobenzoylamino ]propyl ester. <br />                                                                                10 = TFA-5400 = N,N&apos; -Bis(2,3-dihydroxypropyl)-2,4,6- <br /> t   correspondence addressed.                             triiodo-5-(2,2,2-trifluoroacetamido)isophthalamide. <br />  <br />  <br /> Fig. 1. Molecular structures numbering   13C   NMR carbon atoms N-acetyl cyclized iodixanol 1, cyclized iodixanol <br /> 2 deacetyl iodixanol 3. <br />  <br />  <br /> Origin alternative synthesis                                    intermediate deacetylated basic  <br />                                                                     ditions aqueous methanol 1. <br /> Partial loss acetic acid iodixanol generally <br /> occur hydrolysis solvolysis conditions form <br /> deacetyl iodixanol 3. synthesis 3 based            Acute intravenous toxicity <br /> ability trifluoroacetamides undergo solvolytic cleav- <br /> age easily corresponding acetamide.               Deacetyl iodixanol 3, N-acetyl cyclized iodixanol 1 key step 3 alkylation 6 TFA-5400-                cyclized iodixanol 2 tested acute toxicity mice. <br /> bromohydrin 7 basic aqueous medium. bromo-                   administration 2 3 caused effects clini- <br /> hydrin 7 prepared 5 bromine aqueous                 cal signs body weight development. Mortality solution. 5 prepared compound 4 acetylation             morbidity seen mice trifluoroacetic anhydride (TFAA) - 4-dimethyl-                 1 given. mortality incidence 3/5 aminopyridine (DMAP) followed allylation allyl              dose 14.7 gI kg - 1 1, \vithin lower range bromide (Fig. 2).                                                   ALD (approximated median lethal dose) reported    N-Acetyl cyclized iodixanol 1 formed iodixanol           iodixanol 15-18 gI kg- 1 NMRI mice. s lethal exposed basic conditions 7 elevated temperatures           toxicity 1 probably similar marginally higher room temperature, e.g., solution iodixanol          iodixanol. doses 3, 2 1 injected correspond left contact long strong basic <span id='am-5' about='obo:IMR_0001658' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-6' property="obo:IAO_0000115" content="An atom that has either gained or lost electrons to acquire a chage; for example Na+ and Cl-." datatype="xsd:string"></span><span id='am-7' property="oboInOwl:hasDbXref" content="CHEBI:24870" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-9' property="rdfs:label" content="ion" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:id" content="IMR:0001658" datatype="xsd:string"></span>ion</span> exchange        500, 5000 15000 times range speci- <br /> resin. conditions formation 1 mainly            fied amounts high clinical dose 500 mgI kg - deacetylated forms cyclized iodixanol 2. second            iodixanol. presence 1, 2 3  <br /> reaction strongly diminishes remaining concentration            sidered significance toxicity 1 makes different synthetic approach necessary.            clinical formulation 9 iodixanol. <br />    2 synthesized sequence shown Fig. 3. synthesis 1 based ability acetates undergo solvolytic cleavage easily corre-             Experimental, material methods <br /> sponding acetamides. 1 synthesized 2  <br /> acetylation acetic acid anhydride p-toluene-               UV spectra run Philips PU 8750 UVjVIS spec- <br /> sulfonic acid. Peracetyl cyclized iodixanol 9 formed            trometer. spectra measured Bruker IFS 66. <br />  <br />  <br /> Fig. 2. Preparation deacetyl iodixanol 3. <br />  <br />  <br />  <br /> FAB-MS spectra obtained V6 TRIO-2.                       30 min concave gradient 10 50% <br /> NMR spectra recorded 25&#194;&#176;C Varian VXR-                       acetonitrile water 40 min (flow 1 ml min - , 300 S spectrometer DMSO-d6 solvent                       improve detection limits quantification, 1% vjv TMS internal reference. <span id='am-1' about='obo:IMR_0000947' typeof='owl:Thing obo:IMR_0000001'><span id='am-2' property="oboInOwl:id" content="IMR:0000947" datatype="xsd:string"></span><span id='am-3' property="rdfs:label" content="chemical" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>Chemical</span> shifts                 RP-18 method uses &apos;high-low&apos; procedure 12 com- <br /> reported ranges single resonances split                  bines data obtained sample preparations dif- presence numerous rotational isomers 10                  ferent concentrations (2.5 mg ml- 1 25 mg ml- 1). lution 25 &#194;&#176;C. chemical shift assignments C-atom                amino column utilised Supelcosil LC-NH2, Su- <br /> numbers valid simulated BC NMR spec-                    pelco column (cat.  5-8338, 5 }Jm, 0.25 m long tra 11 corresponding compounds. Elemental analy-                  4.6 mm internal diameter). chromatographic pa- <br /> ses performed lIse Beetz, Mikroanalytisches                      rameters linear gradient 85-66 % acetonitrile <br /> Laboratorium, Postfach 1164, D-96301 Kronach, Ger-                       water 25 min (flow 2.5 rol min - 1).  preparative HPLC work carried Jobin Yvon Prepamatic LC - II using self-packed                     Acute intravenous toxicity. Male NMRI mice, weighing <br /> axial compression column 80 mm <span id='am-11' about='oboInOwl:id' typeof='owl:Thing'>ID</span>, reversed-                     20 &#194;&#177; 2 g injected single dose 3, 1 2 <br /> phase mode. column packed slurry                      intravenously tail rate 1.2 ml min - 1. taining isopropyl alcohol. separation monitored                  animals fed standard mouse diet (Ewos R3 pel- refractive index coupled series UV detector.                lets) water ad libitum. 4-10 mice group analytical HPLC performed using meth-                     dosed according Table 1. Clinical signs, body weight <br /> ods, RP-18 column amino-column sys-                     mortality registered period 7 days. <br /> tem. Substances detected UV spectrophoto-                      low aqueous solubility 3 formulated <br /> metric detection (254 nm). RP-18 column                       DMSO (9.24%) final iodine concentration utilised Brownlee Labs column (cat.  OD-5A, 5 }Jm,                  17 mgl ml- 1. DMSO given vehicle <br /> 0.25 m long 4.6 mm internal diameter). chro-                  group equivalent volumes given mice <br /> matographic parameters RP-18 HPLC method                          dosed 3. 1 formulated final concentration linear gradient 3-10% acetonitrile water                  300 mgl ml- 1 87 % iodine content  <br />  <br /> Fig. 3. Decomposition iodixanol 8 high pH forming N-acetyl cyclized iodixanol 1 cyclized iodixanol 2. <br />  <br />  <br />  <br /> Table 1. Dosages mortality mice single intra- <br /> venous injection 1, 2 3; mortality expressed       Preparation deacetyl iodixanol 3. <br /> cidence. <br />                                                                   Trifluoroacetylation oj 4. Trifluoroacetic anhydride <br />                                        Dose           Mortality <br /> Test substance                         (gl kg- 1 )    day 7    (TFAA, 845 mmol, 177.5 g, 117.5 ml) 4-N,N&apos;-di- <br />                                                                   methylaminopyridine (DMAP, 1.78 mmol, 200 mg) Deacetyl iodixanol 3                   0.4            0/4         added suspension 4 (141.8 mmol, 100 g) toluene <br />                                        0.6            0/4         (500 ml) 20-25 0 C. reaction mixture stirred                                        0.8            0/4         40 &#194;&#176; C. 30 min solid material dissolved. Stir- <br />                                        1.0            0/4 <br />                                                                   ring 40&#194;&#176;C continued 1 day. mixture N-acetyl cyclized iodixanol 1 (87%)    14.7           3/5         evaporated dryness redissolved methanol-wa- <br /> Cyclized iodixanol 2                   5.4            0/10        ter (400 ml/40 ml). Activated carbon (5 g) added DMSO                                   0.50      ml   0/4         mixture stirred 60-70 0 C 30 min.  <br />                                        0.75      ml   1/4         lution filtered cold filtrate evaporated                                        1.00      ml   0/4         dryness. Yield: 106.7 g, 133.2 romol, 94% TFA-5400 10. <br />                                        1.20      ml   0/4 <br />                                                                   Allylation 10. 10 (124.8 romol, 100 g) dissolved                                                                   N,N&apos; -dimethylacetamide (DMA, 400 ml) potassium <br /> 1. 2 formulated iodine concentration 50 mgI          carbonate (149.8 mmol, 20.7 g, 1.2 equiv.) added. <br /> ml - 1. low solubility 3 2,         Allyl bromide (149.8 mmol, 18.1 g, 12.6 ml, 1.2 equiv.) <br /> volume limits 1.2 ml 20 g mouse, 5.4 gI kg- 1          added slowly reaction mixture. Stirring 1.0 gI kg - 1, respectively maximum dose.                 continued room temperature 1 day. Additional allyl <br />  <br />  <br /> 740 <br />                                                                                                       IODIXANOL PRODUCTS <br />  <br />  <br /> bromide (12.4 mmol, 1.5 g, 1.05 ml, 0.1 equiv.) added      suspension allowed stand room temperature stirring continued room temperature 1 day.      stirring 1 h filtered using Millipore <br /> Acetic acid (8.6 mt) added mixture             filter. filtrate evaporated dryness (50&#194;&#176; C/ <br /> evaporated dryness high vacuum. residue           20 mbar) residue dried vacuo (50&#194;&#176;C/1 dried 50&#194;&#176;C vacuo suspended water              day). Recovery: 24.5 g 3 (86.2%). <br /> (300 ml) intensive stirring 4-6 h. white crys- <br /> talline substance formed filtered cold. filter     Characterization analysis 3. <br /> cake washed cold water dried (50&#194;&#176;CI               Isomerism. N-acetyl group form <br /> 50 mbar/l day). Yield: 88.1 g, 104.7 mmol, 84% TFA-            exo/endo isomers 1o restricted rotation allyl-5400 5, purity 83 %.                                     N bond. carbon atom chain                                                                central carbon atom bridge chiral form <br /> Hydroxybromination 015. 5 (11.9 mmol, 10.0 g) sus-         32 RIS isomers. <br /> pended water (1.1 1) 50 &#194;&#176;C. solution cooled          HPLC. Achiral column material separate op- O&#194;&#176;C. solution bromine (13.1 mmol, 2.1 g,               tical isomers resulting chiral carbon atoms. 1.1 equiv.) water (200 ml) added slowly 2 h        resolution usually separate types rotamers suspension dissolved. Amberlite        exolendo isomers. analytical HPLC (RP-18 <br /> IRA-68 ion exchange resin (20 ml) added stirred        column amino column) shows peaks 0 &#194;&#176;C 30 min. ion exchange resin filtered    exo/endo isomerism tR = 35.2 + 37.1 min filtrate freeze dried. Yield: 10.5 g, 11.2 mmol,   t R = 10.8 + 11.5 min, respectively. purity 94 ~~ TFA-5400-bromohydrin 7.                                  99.1 area % (RP-18 column) 97.1 area % <br />                                                                (amino column). <br /> Alkylation 016 7. 6 (51.14 mmol, 38.2 g, 1.2 equiv.)          Elemental anal:  C25.85; H 2.83; N 5.83; dissolved water (200 ml) 50&#194;&#176;C pH 12.0. 7             50.77. Calc. C33H4216N6014: C 26.28; H 2.81; N 5.57; <br /> (42.64 mmol, 40.0 g) added slowly 2 h. pH         50.49. TLC: R(&apos;values similar iodixanol kept constant 12.0 2 days/room temperature.         silica RP-18. silica: methyl acetate-methanol- product precipitated. reaction mixture            acetic acid = 6:3: 1; R r = 0.5; ethyl acetate-methanol-ace- <br /> neutralized, evaporated dryness, resuspended             tic acid=6:3:1; R r =0.35; RP-18 W/UV254 &apos;Mach- <br /> 400 ml 80% methanol, diluted water 50% metha-          erey-Nagel&apos; (cat.  811071): methanol-water = 2:8; <br /> nol filtered. filter cake washed 500 ml       R r = 0.6. M.p. 295-296&#194;&#176;C. IH NMR, 13C NMR. ob- <br /> water dried (16 g, 88 area % purity). filtrate     served IH 13C NMR chemical shifts 3 sum- <br /> treated IRA-68 AMB-200 ion exchange resin             marized Table 2 Table 3, respectively. results ion exchanger filtered  filtrate 3     13C NMR spectrum simulation 3 given evaporated drynes s (60 g, 61 % purity) purified     Table 3. UV: C= 0.949 x 10- 5 mol 1-1 (H 20); <br /> preparative HPLe.                                              Amax = 243 nm; E = 0.447; log &#194;&#163; = 4.652. IR13 (KBr): 3400, <br />                                                                3250 (s, N-H, O-H), 3100 (m, N-H), 2940, 2880 (m, <br /> Purification preparative HPLC. 3 ion exchanged       C-H), 1640 (vs, C = 0 primary amide sidechains), 1550 <br /> using mixed bed ion exchanger. yield ion ex- <br /> change approx. 85 %. 99 grams dissolved                                                                (s, C =    &#194;&#176;primary amide sidechains), 1400, 1280 (m, C5 <br />                                                                C-H), 1115, 1040 (m). Solubility water: 10 g 1- 1; 510 ml 20% methanol RO water filtered           aqueous iodixanol (350 mg ml): 30 g 1- 1. FAB-MS: mlz 0.45 Jlm filter chromatography. repetitive        (% reI. int.) = 1509 (100, M + H); 1383 (65, M + 2H - ; <br /> cycles run injecting 16.5 g/85 ml cycle.       1257 (25, M + 3H - 21); 1129 (15, M + 2H - 31). fractions taken worked vacuum <br /> evaporation. Fractions 3 4 (36.43 g) 99.2% pure       Preparation olN-acetyl cyclized iodixanoll. suspension <br /> 3 (stationary phase: Merck Lichroprep RP-18, 60  25-         2 (3.0 g, MW 1379.77, 2.17 mmol) p-toluene- <br /> 40 Jlm, 700 g, Vd = 1 1; mobile phase: solvent = 20%         sulfonic acid (0.06 g, MW 172.22, 0.34 mmol) acetic <br /> methanol water; solvent B = 80% methanol water; <br /> flow rate: approx. 85 ml min - 1; elution pressure: 7.6- <br /> 7.8 bar; cycle time: 80 min).                                  Table 2. 1 H NMR chemical shifts assignments 1, 2 <br />                                                                3 DMSO . <br /> Final treatment biological purpose. 3 (28.4 g, <br />                                                                Chemical         Chemical shift   Chemical shift   Chemical shift <br /> 18.8 mmol) dissolved water (2  room tem-           group            1 (ppm)       2 (ppm)       3 (ppm) <br /> perature. Traces remained undissolved. Ion exchange <br /> resin IRA-68 (ca. 0.8 g) 200 (ca. 0.8 g)           NH             8.8-8.0          8.8-7.9         8.7-8.0 <br /> added pH remained stable 6.5. Activated car-      Ar-NH                              5.4-5.2         5.1 <br />                                                                OH                4.9-4.4          4.9-4.4         4.9-4.4 <br /> bon (ca. 0.5 g) added solution stirred       CH, CH 2          4.3-2.7          4.3-2.9         4.4-2.8 <br /> room temperature 1 h. suspension filtered          CH 3 (endo)   2.34-2.02        2.28-2.24        2.25 <br /> using Millipore filter. Neutral aluminium oxide (grain       CH 3 (ring)   2.34-2.02 <br />                                                                CH 3 (exo)    1.88-1.72        1.85-1.77        1.78 <br /> size 50-200 Jlm, ca. 0.5 g) added filtrate.  <br />                                                                                                                             741 <br />  PRIEBE ET AL. <br />  <br />  <br /> Table 3. 13C NMR chemical shifts assignments             Table 4. 13C NMR chemical shifts assignments deacetyl iodixanol 3 DMSQ-d6 .                               N-acetyl cyclized iodixanol 1 DMSQ-d6 . <br /> Chemical shift      Simulation 11      Assignment            Chemical shift      Simulation 11      Assignment 3 (ppm)          (ppm)              C-atom  Fig.       1 (ppm)          (ppm)              C-atom  Fig. <br />  <br /> 170.2-170.1         171.4&#194;&#177;2.9          16                       170.7-168.7         171.4&#194;&#177;2.9          20 <br /> 169.8-169.4         170.7 &#194;&#177; 1.7        4 11 26 30               170.7-168.7         170.7&#194;&#177;1.7          11 32 28 <br /> 149.8               149.9&#194;&#177;             20                       170.7-168.7         169.6&#194;&#177;0.2          16 <br /> 15 1.4-1 50.5       150.0&#194;&#177;3.1          5 9 22 24                166.2-165.7         166.1 &#194;&#177;0.5         4 <br /> 147.8-147.4         147.6&#194;&#177;1.8          7                        151.3-150.7         150.0&#194;&#177;3.1          926 24 <br /> 101.3-99.5           98.6&#194;&#177;4.4          68                       147.5-146.6 <br />  92.3-91.5           98.6&#194;&#177;4.4          21 25                    144.7               147.6&#194;&#177; 1.8         22 <br />  83.3-82.9           89.9&#194;&#177;2.9          1023                     142.0-14 1.4        142.411.7          6 <br />  70.0-69.7           70.4&#194;&#177;0.7          2132832                  133.1               132.5&#194;&#177;3.4          5 <br />  68.4-68.0           69.7&#194;&#177;             18                       130.5-130.0         130.2&#194;&#177;0.5          7 <br />  63.8-63.7           64.3&#194;&#177;0.6          1 14 29 33               100.5-99.0           98.6&#194;&#177;4.4          2327 <br />  54.9-54.2           53.4&#194;&#177;             17                        96.5-95.6 <br />  53.6-53.3           50.0t             19                        92.2-91.9           89.9&#194;&#177;2.9          25 <br />  42.4-42.2           43.0tO.6          3122731                   90.7-90.4           89.0&#194;&#177;6.8          8 <br />  22.7-22.1           22.9tO.7          15                        89.4                82.317.6          10 <br />                                                                  77.7-76.7           77.4&#194;&#177;0.2          18 <br />                                                                  70.7-69.6           70.4&#194;&#177;0.7          2 13 30 34 <br />                                                                  63.8-63.4           64.3&#194;&#177;0.6          1143135 <br /> acid anhydride (15 ml) heated 70&#194;&#176;C. 3 h            52.2-51.4           51.9&#194;&#177;0.0          19 <br />                                                                  44.5-43.9           45.4&#194;&#177;0.0          17 reaction mixture homogeneous solution            42.5-41.9           43.0&#194;&#177;0.6          3122933 <br /> 9. solution evaporated dryness redis-             23.7; 22.4          22.910.7          15 21 <br /> solved methanol-\vater (80:20~ 15 ml). order deacetylate O-acetyl groups pH solution adjusted 11.5. 3 h stirring room tem- <br /> perature solution neutralized evaporated         C3sH431sN601S: C 29.56; H 3.05; N 5.91; 1 44.61. TLC: <br /> dryness. crude 1 (3.5 g) purified preparative        TLC silica: chloroform-methanol-acetic <br /> HPLC.                                                           acid = 50:50:2; R r: 0.52. M.p. 234-236&#194;&#176;C. IH NMR, l3C <br />                                                                 NMR: observed 1Hand l3C NMR chemical shifts Purification preparative HPLC. 1 (101.25 g) dis-         1 summarized Table 2 Table 4, respectively. <br /> solved 380 ml 18 % methanol RO-water filtered         results 13C NMR spectrum simulation 1 0.45 Jlm filter chromatography.        given Table 4. UV: C= 1.077 x 10- s mol 1-1 (H 2 0); <br /> petitive cycles run injecting 25.3 g/95 ml         Amax = 240 nm; E = 0.610; log E = 4.753. (KBr): 3360, <br /> cycle. fractions taken worked          3250 (s, N-H, O-H), 3080 (m, N-H); 2930, 2880 (m, vacuum evaporation. Based total area %              C-H), 1745, 1700 (s, C = 0 N-acetyl), 1640 (vs, C = 0 <br /> analytical HPLC chromatogram RP-18, fractions <br /> 3, 4 5 (22 g)  98.5 % pure (stationary phase: <br />                                                                                                             &#194;&#176; <br />                                                                 primary amide sidechains), 1570 (s, C = primary amide <br />                                                                 sidechains); 1370, 1390 (s, (5 C-H acetyl); 1030, 1050 <br /> Merck Lichroprep RP-18, 60  25-40 Jlm; mobile                 (m). FAB-MS: m (% reI. int.) = 1423 (100, M + H); <br /> phase: solvent = 21 % methanol water; solvent              1297 (70, M + 2H - ; 1171 (38, M + 3H - 21); 1042 (20, <br /> B = 80% methanol water; flow rate: approx. 85 ml             M + H - 31). <br /> min -1; elution pressure: 8.9-9.1 bar; cycle time: 80 min). <br />                                                                 Preparation cyclized iodixanol 2. lodixanol 8 (110 g, <br /> Characterization analysis oj 1.                             71 mmol) dissolved solution sodium hydrox- <br /> Isomerism. rotation N-acetyl group connected         ide (35.6 g, 0.89 mol) water (3.2 1). solution oxazine ring fixed.  N-acetyl       heated 75 &#194;&#176;C 20 h. mixture neutralized <br /> group form 2 exo/endo isomers 10 restricted ro-        cone. HCI solvent removed  <br /> tation N bond. carbon atom            duced pressure. residue dissolved methanol chain position 2 benzoxazine ring           (1. 3 1) 50 &#194;&#176;C. solution cooled 0 &#194;&#176;C chiral structure forms 32 R/S isomers.                  precipitated salts removed filtration. filtrate <br />       HPLC. resolution usually insufficient sep-      treated active carbon 40-50 &#194;&#176;C 1.5 h  <br /> arate types rotamer exo/endo isomers.       fore filtration. filtrate evaporated dry- <br /> analytical HPLC (RP-18 column amino column)                 ness gave crude 2 (96.7 g, 88.3 % purity, 87 % yield). <br /> shows peaks exo/endo isomerism t R = 35.5 + 43.1 min t R = 8.7 + 11.0 min, respectively.   Purification preparative HPLC. 2 (127 g) dissolved purity 99.4 area % (RP-18 column)           500 ml 21 % methanol water filtered 99.1 area % (amino column). Elemental anal:                 0.45 nm filter chromatography. repetitive  C29.27; H 3.08; N 6.08; 1 44.68. Calc.               cycles run injecting approx. 25.4 g/100 ml  <br />  <br /> 742 <br />                                                                                                        IODIXANOL PRODUCTS <br />  <br />  <br /> cycle. fractions taken fractions 2-8       Table 5. 13C NMR chemical shifts assignments cy- <br /> worked vacuum evaporation. Based total area           c1ized iodixanol 2 DMSO-d6 . <br /> % analytical HPLC chromatogram RP-18              Chemical shift         Simulation 11     Assignment fractions 3-6 (20.3 g) &gt; 99.1 % pure (stationary          2 (ppm)             (ppm)             C-atom  Fig. <br /> phase: Merck Lichroprep RP-18, 60  25-40 J.!m, 700 <br /> gram, V.d. = 11; mobile phase: solvent = 21 % methanol       water, solvent B = 80% methanol water; flow rate:     <br /> approx. 86 ml min - 1; elution pressure: approx. 11 bar;        <br /> detection: RI sens. 8, UV function; cycle time:        <br /> 75 min).                                               <br /> Characterization analysis oj 2.                            <br /> Isomerism. N-acetyl group form 2 exo/endo iso-       <br /> mers 10 restricted rotation N bond.          carbon atom chain position 2   <br /> benzoxazine ring chiral 32 R/ S isomers             <br /> formed.                                                         <br />    HPLC. resolution insufficient separate    <br /> syn/anti cis/trans isomers expect isomers      separated. analytical HPLC (RP-18 column          amino column) shows peaks probably          exo/endo isomerism tR = 27.9 + 34.4 + 35.0 min         t R = 9.6 + 12.7 + 14.9 min, respectively. Isomerisation <br /> studies showed peaks belong product. purity 99.5 area % (RP-18 <br /> column) 99.5 area % (amino column). Elemental <br />                                                                 <br /> anal:  C 28.81; H 3.14; N 5.74; 45.92. Calc. C33H41IsN6014: C 28.72; H 2.99; N 6.09; 45.97. TLC:          <br /> TLC silica: chloroform-methanal-acetic             <br /> acid = 50:50:5; spots R r: 0.52 0.29. Solu-        <br /> bility: water: &quot;&quot; 2 mg ml- measured TLC.  <br />                                                              <br /> tempts make solution 2 mgI ml- (4.3 mg ml- 1)        water failed. Attempts make solution 20 mgI        <br /> ml- (43 mg ml- 1) methanol failed. M.p. 225-230 o e.       <br /> IH NMR, l3C NMR. observed 1H l3e NMR                   <br /> chemical shifts 2 summarized Table 2              <br /> Table 5, respectively. results 13C NMR spec-        <br /> trum simulation 2 given Table 5. UV:             <br /> C 811xlO-&#194;&#183; s mol 1-1 (H 2 0); Amax =234 nrn;                 <br /> E = 1.036; log E = 4.769. diffuse reflectance measure-   <br /> ment 1.99% 2 KBr: 3360, 3230 (m, N-H, O-H),              <br /> 3070 (m, N-H), 2935, 2880 (w, C-H), 1653, 1630 (vs,       <br /> C = 0 primary amide sidechains), 1570 (s, C = 0 primary      <br /> amide sidechains); 1435, 1390 (s, 8 C-H acetyl), 1036              <br /> (m). FAB-MS: nl (% reI. int.) = 1403 (50, M + Na),              <br /> 1381 (100, M + H), 1277 (25, M + H + Na - ; 1255 (49,         <br /> M + 2H - ; 1129 (10, M + 3H - 21).                               <br />   <br /> </body></html>